File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

TitleMultiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases
Authors
KeywordsEarly-onset multiple myeloma
Prognosis
Survival
Treatment response
Issue Date2019
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal
Citation
Leukemia and Lymphoma, 2019, v. 60 n. 2, p. 471-476 How to Cite?
AbstractA small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.
Persistent Identifierhttp://hdl.handle.net/10722/271992
ISSN
2020 Impact Factor: 3.28
2015 SCImago Journal Rankings: 1.202
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJurczyszyn, A-
dc.contributor.authorDavila, J-
dc.contributor.authorKortüm, KM-
dc.contributor.authorJayabalan, DS-
dc.contributor.authorVij, R-
dc.contributor.authorFiala, M-
dc.contributor.authorMilunovic, V-
dc.contributor.authorChim, CS-
dc.contributor.authorWiśniewska-Piąty, K-
dc.contributor.authorWaszczuk-Gajda, A-
dc.contributor.authorCrusoe, E-
dc.contributor.authorHajek, R-
dc.contributor.authorRobak, P-
dc.contributor.authorRaźny, M-
dc.contributor.authorZawirska, D-
dc.contributor.authorBittrich, M-
dc.contributor.authorNahi, H-
dc.contributor.authorLiu, J-
dc.contributor.authorCastillo, JJ-
dc.contributor.authorVesole, DH-
dc.date.accessioned2019-07-20T10:33:34Z-
dc.date.available2019-07-20T10:33:34Z-
dc.date.issued2019-
dc.identifier.citationLeukemia and Lymphoma, 2019, v. 60 n. 2, p. 471-476-
dc.identifier.issn1042-8194-
dc.identifier.urihttp://hdl.handle.net/10722/271992-
dc.description.abstractA small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal-
dc.relation.ispartofLeukemia and Lymphoma-
dc.subjectEarly-onset multiple myeloma-
dc.subjectPrognosis-
dc.subjectSurvival-
dc.subjectTreatment response-
dc.titleMultiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases-
dc.typeArticle-
dc.identifier.emailChim, CS: jcschim@hku.hk-
dc.identifier.authorityChim, CS=rp00408-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/10428194.2018.1480766-
dc.identifier.pmid30033832-
dc.identifier.scopuseid_2-s2.0-85050555358-
dc.identifier.hkuros299553-
dc.identifier.volume60-
dc.identifier.issue2-
dc.identifier.spage471-
dc.identifier.epage476-
dc.identifier.isiWOS:000463555600025-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1026-8022-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats